Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Ann Rheum Dis. 2019 Sep 20;79(3):332–338. doi: 10.1136/annrheumdis-2019-216109

Figure 1.

Figure 1

Kaplan-Meier curves for persistent arthritis based on immunotherapy regimen, irAEs, and tumour response. (A) demonstrates increased arthritis persistence in those treated with combination ICI therapy. (B) shows more persistent arthritis in those with >2 additional irAEs. (C) shows that patients with a tumour response of complete response or partial response (CR/PR) had more persistent arthritis compared with those with stable disease or progressive disease (SD/PD) at follow-up. IA, inflammatory arthritis; ICI, immune checkpoint inhibitor; irAEs, immune-related adverse events.